Pharvaris (NASDAQ:PHVS – Get Free Report) and Caribou Biosciences (NASDAQ:CRBU – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, dividends, valuation, institutional ownership, earnings, profitability and risk.
Institutional and Insider Ownership
77.5% of Caribou Biosciences shares are held by institutional investors. 11.8% of Pharvaris shares are held by insiders. Comparatively, 8.5% of Caribou Biosciences shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
Volatility & Risk
Pharvaris has a beta of -2.34, indicating that its stock price is 334% less volatile than the S&P 500. Comparatively, Caribou Biosciences has a beta of 2.27, indicating that its stock price is 127% more volatile than the S&P 500.
Analyst Recommendations
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pharvaris | 1 | 2 | 10 | 0 | 2.69 |
| Caribou Biosciences | 1 | 0 | 2 | 1 | 2.75 |
Pharvaris presently has a consensus target price of $49.18, suggesting a potential upside of 66.89%. Caribou Biosciences has a consensus target price of $8.67, suggesting a potential upside of 275.18%. Given Caribou Biosciences’ stronger consensus rating and higher possible upside, analysts plainly believe Caribou Biosciences is more favorable than Pharvaris.
Profitability
This table compares Pharvaris and Caribou Biosciences’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pharvaris | N/A | -67.56% | -61.13% |
| Caribou Biosciences | -1,189.14% | -84.17% | -60.51% |
Valuation & Earnings
This table compares Pharvaris and Caribou Biosciences”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Pharvaris | N/A | N/A | -$198.79 million | ($3.18) | -9.27 |
| Caribou Biosciences | $11.20 million | 20.45 | -$148.12 million | ($1.42) | -1.63 |
Caribou Biosciences has higher revenue and earnings than Pharvaris. Pharvaris is trading at a lower price-to-earnings ratio than Caribou Biosciences, indicating that it is currently the more affordable of the two stocks.
Summary
Caribou Biosciences beats Pharvaris on 10 of the 14 factors compared between the two stocks.
About Pharvaris
Pharvaris N.V., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases. The company develops PHA121, a small molecule bradykinin B2-receptor antagonist for the treatment of hereditary angioedema (HAE). It also develops PHVS416, an on-demand, rapid exposure soft capsule for patients suffering from acute HAE attacks which is under Phase 2 clinical trial; and PHVS719, a prophylactic extended-release tablet for HAE patients which is under Phase 1 clinical trial. The company operates in the Netherlands, Switzerland, and the United States. Pharvaris N.V. was incorporated in 2015 and is based in Leiden, the Netherlands.
About Caribou Biosciences
Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.
Receive News & Ratings for Pharvaris Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pharvaris and related companies with MarketBeat.com's FREE daily email newsletter.
